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Objective. We hypothesised that the endothelial dysfunction is associated with early glucose dysregulation and/or atherosclerosis
risk factors in nondiabetic women with a previous history of gestational diabetes (pGDM). Material/Methods. Anthropometric
parameters, glucose regulation (OGTT), insulin resistance (HOMA), lipids, biomarkers of endothelial dysfunction, and
inﬂammation were evaluated in 85 women with pGDM and in 40 controls 2–24 months postpartum. Results. The pGDM group
consisted of 67% normoglycemic women (pGDM-N) and 33% with prediabetic state (pGDM-P). The BMI, waist circumference,
fasting and 2h glucose (OGTT), soluble adhesion molecules, tissue plasminogen activator antigen, high sensitivity C-reactive
protein, total-, LDL-cholesterol, and triglycerides/HDL-cholesterol ratio were higher in the pGDM women compared with the
controls. After adjustment for BMI and fasting glucose, only higher triglycerides, higher TG/HDL and lower HDL-cholesterol
were associated with pGDM. The pGDM-P diﬀered from pGDM-N for only higher triglycerides and TG/HDL. The plasma level
of sE-selectin was not independently associated with glucose concentration in pGDM group. sE-selectin level correlated with
triglycerides, TG/HDL, plasminogen activator inhibitor-1 antigen, and sICAM-1. Conclusions. sE-selectin level correlated with
components of metabolic syndrome, but only the atherogenic lipid proﬁle was independently associated with a previous history
of GDM in nondiabetic women 2–24 months postpartum.
1.Introduction
Women with the previous history of gestational diabetes
mellitus (pGDM) have a signiﬁcantly increased risk of type
2 diabetes and cardiovascular disease in the next years
after delivery [1]. Very important problem is both GDM
and its future consequences are drastically increasing public
health and global problem which requires speciﬁc preventive
strategies.
In the years postpartum, women with pGDM have an
increased cardiometabolic derangement, including vascular
risk factors and early vascular dysfunction [2–4]. Several
studies performed early (6 weeks-2 years) after delivery have
found the association of cardiovascular risk factors with
glucose intolerance, and in particular with type 2 diabetes
[5, 6].
Shah et al. [1] have observed that there is an increased
prevalence of metabolic syndrome in the third month
postpartum among women with even mild glucose intol-
erance during pregnancy. Thus, it is possible that dif-
ferent stages of glucose dysregulation diagnosed during
pregnancy are associated with early cardiovascular risk
postpartum [7]. It has been suggested that the association
between prediabetic state or diabetes and cardiovascular
disease may be mediated through endothelial dysfunction
[8, 9].2 International Journal of Endocrinology
Soluble forms of adhesion molecules are released from
shedding or proteolytic cleavage from the endothelial cell
surface and may reﬂect overexpression of their respective
membrane-bound forms [10]. Circulating levels of some
endothelial-derived factors, soluble cell adhesion molecules,
von Willebrand factor (vWF), tissue plasminogen activator
(t-PA), and plasminogen activator inhibitor type1 (PAI-1)
have been linked to the risk of type 2 diabetes in populations
without pGDM [8, 11–13]. There are few controversial
data concerning the associations between levels of soluble
adhesion molecules and glucose regulation status in women
with the pGDM. Studies simultaneously have assessed the
associations with soluble adhesion molecules and hemo-
static endothelial activation biomarkers with prediabetic and
proatherogenic state in women with the pGDM [14–16].
In current study we hypothesized that early (2–24
months) endothelial dysfunction is associated with the
development of early glucose dysregulation and/or the other
atherosclerosis risk factors and may be the potential target
included in preventive strategies in women with the pGDM.
The aim of current study was to assess selected parameters
of dysfunction of endothelium such as concentration of
solubleE-selectin(sE-selectin),solublevascularcelladhesion
molecule-1 (sVCAM-1), and soluble intracellular adhesion
molecule-1 (sICAM) in women with pGDM 2–24 months
postpartum.
2.MaterialandMethods
2.1. Patients and Subjects. The research was conducted at the
Diabetes and Pregnancy Unit at the Dr. J. Biziel University
Hospital in Bydgoszcz, Poland, between 2005 and 2007.
A total of 85 Caucasian women with single gestations
complicated by previous GDM (pGDM) and 40 women
with normal glucose status during pregnancy (previous
normalglucosetolerance—pNGT)asthecontrolgroupwere
evaluated in the period of 2–24 months after delivery.
All subjects ingested at least 150g carbohydrates a day
and refrained from exercise for at least 3 days before the
study. None of the participants had renal, hepatic, or car-
diovascular disease. None of them were taking medications
that aﬀected lipid or carbohydrate metabolism. Women with
a family history of diabetes mellitus, in addition of infectious
processes, under stress as well as, those who were smoking,
were not included.
GDM was diagnosed according to the modiﬁed criteria
of the World Health Organization [17] after performing a
fastingand2h75goralglucosetolerancetest(OGTT).These
modiﬁedcriteriaarecommonlyusedinPolandandarebased
on taking fasting glucose concentration of <5.6mmol/L as a
norm. This test was carried out in all pregnant women with a
screeningtest(GCT-50-goralglucosechallenge)showing2h
glucose value equal to or above 7.8mmol/L. The screening
test was performed during the ﬁrst prenatal visit in all study
groups and was repeated in the 24–28 weeks of gestation.
At the postpartum assessment, all participants under-
went a physical examination that included anthropometric
measurements. Waist circumference was measured at the
smallest circumference between the ribs and iliac crest. BMI
was calculated as weight in kilograms divided by the squared
height in meters.
The standard 75g 2h OGTT was performed in order
to assess glucose tolerance after delivery. The current status
of glucose regulation was deﬁned according to the modiﬁed
WHO recommendations.
Venous blood (4.5mL) for endothelial markers tests
was collected in a fasting state into cooled tubes (Becton
Dickinson Vacutainer System, Plymouth, UK) containing
0.13mol/L trisodium citrate (the ﬁnal blood-anticoagulant
ratio was 9:1) after 30min of rest between 7.00 and 9.00
am and after a 12h overnight fast. The blood samples were
immediately mixed and centrifuged at 3000× ga t+ 4 ◦C
for 20min. The obtained platelet-poor plasma was divided
into 200μL Eppendorf-type tubes, and then samples were
frozenat−86◦Cuntilassayed,butnolongerthansixmonths.
Blood for serum lipids; insulin concentration, and high
sensitivityC-reactiveprotein(hsCRP)wascollectedinatube
containing no anticoagulant (Becton Dickinson Vacutainer
17490, Plymouth, UK), and the serum was separated by
centrifuging at 2500× gf o r1 5m i na n dk e p ta t+ 4 ◦C until
analyzed.
Serum glucose levels in samples from the OGTT were
analyzed using the glucose hexokinase method on the
automatic analyzer (Olympus Diagnostica GmbH, Ireland).
Serum insulin concentration was determined using an
immunochemical assay (8K41 Architect Insulin, Abbott
Diagnostics, Denka Seiken, Japan) performed in the Archi-
tect Insulin analyzer (Abbott Diagnostics, Denka Seiken,
Japan). Serum concentrations of triglycerides and total
LDL and HDL cholesterol were measured by enzymatic
techniques (Olympus Diagnostica GmbH, Ireland) on the
Olympus automatic analyzer (Olympus Diagnostica GmbH,
Ireland).
The concentration of t-PA:Ag was determined by
Enzyme-Linked Immunosorbent Assay (ELISA)- ASSER-
ACHROM t-PA (Diagnostica Stago, Asnieres, France),
and PAI-1:Ag was determined by ELISA-ASSERACHROM
PAI-1-(Diagnostica Stago, Asnieres, France), vWF:Ag was
assessed by ELISA-STA-Liatest VWF:Ag (Diagnostica Stago,
Asnieres, France), C-reactive protein (CRP) was measured
with a high-sensitivity assay by test IMUCLONE CRP (hs)
ELISA, C-Reactive Protein-ADI, using reagents from the
American Diagnostica. Soluble sICAM-1 and sVCAM-1
were measured by using reagents from Bender Medsystems
(Biomedica, Poland), and soluble E-selectin was determined
by testing E-selectin (ELAM-1) antibody using reagent from
IBL (Hamburg, Germany).
The homeostasis model assessment of insulin resistance
(HOMA-IR) index was calculated as a sensitivity index
of the insulin sensitivity of the whole body. The HOMA
index was calculated by multiplying the fasting glucose level
(millimoles per liter) by the fasting insulin level (microunits
per milliliter) and dividing the product by 22.5 [18].
2.2. Statistical Methods. The statistical analysis was car-
ried out using Statistica 8,0 (StatStoft, Cracow, Poland).International Journal of Endocrinology 3
The analyzed parameters were tested for normal distribution
using the Shapiro-Wilk test. Variables were not normally
distributed; U Mann Whitney test was used. Results shown
are median (interquartile range) or frequencies (percent-
ages). These results were further adjusted for BMI and
fasting glucose. The P values <0.05 were considered statis-
tically signiﬁcant. Spearmans correlation coeﬃcients were
calculated to determine if there were associations between
measured parametric values and sE-selectin level in the
group with the history of GDM. To investigate the associa-
tion between glucose level and plasma levels of biomarkers
of endothelial dysfunction, all pGDM women were divided
into two subgroups in accordance with low and high-glucose
concentration within the prediabetic range. The high-
glucose subgroup comprised of women with fasting glucose
equal or above 6.4mmol/L and <7 . 8 m m o l / La t2 ha f t e r
75g glucose challenge (OGTT), women with fasting glucose
<5.6mmol/L and >8.9mmol/L at 2h, and women with fast-
ing glucose equal to or above 6.4mmol/L and >8.9mmol/L
at 2h. Other pGDM women were included into the low-
glucose subgroup. We compared plasma levels of endothe-
lial dysfunction biomarkers in these subgroups. Addi-
tionally, the association of sE-selectin concentration with
fasting glucose was examined by multiple logistic regression
analysis.
2.3. Results. At the postpartum assessment of 85 women
with pGDM and 40 women with normal glucose regulation
during pregnancy (previous normal glucose tolerance—
pNGT group), 7 women (8.24%) in pGDM group had
impaired fasting glucose with normal glucose tolerance at
2h OGTT (IFG/NGT), 16 (18.82%) normal fasting glucose
with impaired glucose tolerance at 2h OGTT (NFG/IGT),
5 (5.88%) impaired fasting glucose with impaired glucose
tolerance at 2h OGTT (IFG/IGT), and 57 women (67.06%)
with normal glucose regulation (NFG/NGT). In the pNGT
group all women were classiﬁed as NFG/NGT.
Women in pGDM group had signiﬁcantly higher
levels of fasting glucose, 2h (OGTT) glucose, HbA1c,
sVICAM-1, sICAM-1, sE-selectin, tPA:Ag, BMI, waist cir-
cumference, total cholesterol, LDL-cholesterol, triglycerides,
and triglycerides/HDL-cholesterol ratio and lower HDL-
cholesterol. After adjustment for BMI and fasting glucose,
the pGDM was associated only with higher sVCAM-1,
higher triglycerides, lower HDL-cholesterol, and higher
triglycerides/HDL-cholesterol ratio (Tables 1 and 2).
Women in pGDM-P subgroup diﬀered from pGDM-
N group for higher fasting, 2h (OGTT) glucose and
higher triglycerides and triglycerides/HDL-cholesterol ratio
(Table 2).
Only sE-selectin levels were signiﬁcantly higher in high-
glucose subgroup compared with the low-glucose subgroup,
but this result was eliminated after further adjustment for
BMI (Table 3). In multivariate regression analysis fasting
glucose was associated only with insulin (P = 0.0087 and
HOMA-IR (P = 0.0013).
In pGDM group sE-selectin was signiﬁcantly correlated
with triglycerides (r = 0.32), triglycerides/cholesterol-HDL
ratio (r = 0.2910), PAI-1:Ag (r = 0.2647), tPA:Ag (r =
0.2622), and sICAM-1 (r = 0.2504).
3. Discussion
Among the 85 apparently healthy women with the previ-
ous history of gestational diabetes (pGDM), 33% showed
prediabetic state; 19% impaired glucose tolerance, 8%
impaired fasting glucose and 6% impaired fasting glucose
with impaired glucose tolerance at two hours of oral glucose
tolerance test. These results are in accordance with previous
reports [5].
Our study shows that these nondiabetic women with
pGDM have higher concentrations of cardiovascular risk
factors at average 10 months assessment after delivery in
comparison with women with normal glucose regulation
during pregnancy. The pGDM population was characterized
by higher values of body fat indexes as well as levels of
endothelial dysfunction parameters (sICAM-1, sVCAM-1,
sE-selectin, tPA:Ag) and low-grade inﬂammation (hsCRP)
which coexisted with dyslipidemic lipids proﬁle and compa-
rableinsulinresistance.AfteradjustmentforBMIandfasting
glucose, only higher triglycerides, higher sVCAM-1, lower
HDL-cholesterol, and higher triglycerides/HDL-cholesterol
ratio were associated with pGDM.
Thus, our results suggest that the atherogenic dyslipi-
demia my be speciﬁc and important metabolic feature
of nondiabetic women with pGDM during ﬁrst years
pospartum. It is well known and generally accepted that
this metabolic abnormality is associated with endothelial
dysfunctionandinsulinresistance[19–21].Interestingly,our
current study shows that atherogenic lipids proﬁle in pGDM
nondiabeticwomenisindependentofbothinsulinresistance
and BMI.
Our results are inconsistent with one previous report
suggesting elevated sE-selectin levels during 12–26 months
after delivery only in pGDM women with abnormal glucose
regulation and with other two studies presenting higher sE-
selectin levels irrespectively of glucose regulation status [14–
16] and metabolic abnormalities related to insulin resistance
[16]. Moreover, results of these studies suggest that elevated
level of sE-selectin in post-GDM women is independent of
time since delivery [14, 16].
Thecurrentstudyistheﬁrstinwhichweobservedhigher
plasma levels of sICAM-1, sE-selectin, and tPA:Ag levels with
simultaneously normal levels of PAI-1:Ag and vWF:Ag in
nondiabetic pGDM women with both abnormal and normal
glucose regulation.
Several studies have shown that circulating levels of
ICAM-1, E-selectin [8, 11], tPA:Ag [12, 13], vWF:Ag, and
PAI-1:Ag [12] have been linked to the risk of type 2 diabetes
in populations without the previous history of GDM.
In our study we have found that in the case of non-
diabetic women with pGDM, high-glucose concentrations
within the prediabetic range were associated with higher sE-
selectin levels. This association was eliminated after further
adjustment for BMI. Additionally, in multivariate regression
analysis, fasting glucose was associated only with insulin4 International Journal of Endocrinology
Table 1: Characteristics of women with previous history of GDM (pGDM group) and control participants with normal glucose regulation
during pregnancy (pNGT group).
Variables (units) pGDM (n = 85) pNGT (n = 40) P-values
Age (years) 29.00 (26.00, 35.00) 27.00 (25.00, 35.50) 0.2040
BMI (kg/m2) 23.68 (20.96, 27.54) 22.00 (20.31, 24.33) 0.0098
Waist (m) 0.80 (0.73–0.92) 0.74 (0.69–0.78) 0.0007
HbA1C (%) 5.50 (5.40–5.70) 5.40 (5.30–5.40) 0.4399∗
Fasting plasma glucose (mmol/L) 4.50 (4.61–5.33) 4.72 (4.50–4.78) 0.0001∗
2-h (OGTT) plasma glucose (mmol/L) 6.16 (5.55–7.66) 4.84 (4.77–5.44) 0.1655∗
Insulin (pmol/L) 54.87 (41.67–80,56) 63.20 (54.87–71.53) 0.1755
sVCAM-1 (ng/mL) 1113.53 (419.60–1616.70) 672.05 (455.70–1113.46) 0.00018∗
sICAM-1 (ng/mL) 294.89 (238.73–364.19) 140.40 (121.34–179.90) 0.5053∗
sE-selectin (ng/mL) 28.13 (19.17–43.95) 20.90 (17.11–26.01) 0.0791∗
0.4791∗∗
tPA:Ag (ng/mL) 4.89 (3.53–7.66) 3.50 (2.66–4.64) 0.4058∗
vWF:Ag (%) 104.30 (96.20–122.30) 104.87 (74.96–125.67) 0.4405
PAI-1:Ag (ng/mL) 57.09 (46.28–79.43) 71.36 (50.54–81.80) 0.1371
hsCRP (μg/mL) 1.22 (0.66–2.76) 0.41 (0.22–0.79) <0.0004∗
0.1939∗∗
Total-cholesterol (mmol/L) 5.04 (4.55–5.51) 4.56 (4.27–5.09) 0.9940∗
HDL-cholesterol (mmol/L) 1.53 (1.28–1.73) 1.73 (1.56–1.82) 0.0027∗
0.0449∗∗
LDL-cholesterol (mmol/L) 3.10 (2.79–3.54) 2.57 (2.30–3.05) 0.4022∗
Triglyceride (mmol/L) 0.97 (0.78–12.83) 0.86 (0.67–1.05) 0.0006∗
<0.0001∗∗
Triglyceride/HDL cholesterol 1.52 (1.06–2.63) 1.11 (0.89–1.50) <0.0001∗
<0.0001∗∗
HOMA-IR (%) 1.67 (1.22–2.80) 1.89 (1.58–2.37) 0.3973
NFG/IGT n (%) 16 (18.82) — —
IFG/NGT n (%) 7 (8.24) — —
IFG/IGT n (%) 5 (5.88) — —
NFG/NGT n (%) 57 (67.06) 40 (100) —
Values are median (IQR) or n (%). P values were from U-Mann Whitney test. ∗adjusted for body mass index, ∗∗adjusted for fasting glucose.
concentration and insulin resistance assessed by HOMA-
index. Thus, our results showed that endothelial dysfunction
evaluated by soluble forms of its speciﬁc biomarkers was
not independently associated with glucose dysregulation in
nondiabetic women with pGDM.
In the whole population of pGDM women, sE-selectin
levels correlated positively with other markers of endothelial
dysfunction, tPA:Ag, sICAM-1, and with surrogate mark-
ers of insulin resistance, triglycerides, triglycerides/HDL-
cholesterol ratio, and PAI-1:Ag level. Recently, triglyc-
erides/HDL cholesterol ratio has been suggested to be a
predictor of insulin resistance and of the proportion of
small and dense LDL particles, which is characteristic of
atherogenic phenotype of the metabolic syndrome [22].
Results of our study suggest also that endothelial dys-
function at assessment 2–24 months (average 10 months)
after delivery in nondiabetic women with pGDM is char-
acterized by higher plasma levels of circulating ICAM-1,
sE-selectin, and tPA:Ag in women with normal glucose
regulation as well as pGDM women with prediabetic state,
matched for age, body fat indexes values, inﬂammation, and
PAI-1:Ag level. These observations agree with the previous
studies of Bo et al. performed 6.5 years after delivery
in pGDM women. In this study, they obtained higher
levels of sE-selectin and sICAM-1 and higher intima media
thickness (IMT) values characterized pGDM women, even
those without any components of the metabolic syndrome
except for glycaemia [16]. In all pGDM women, sE-selectin,
sICAM-1, interleukin-6, and hsCRP values were signiﬁcantly
associated with IMT, thus supporting associations of these
biomarkers with pathogenesis of atherosclerosis [16].
Our present ﬁndings contrast with the results of previous
study of Lawrence et al. [15]. These authors have found
clinical and biochemical markers of insulin resistance but
have not shown any associations between sE-selectin levels
and these markers [15]. Additionally, higher levels of sE-
selectin in post-GDM women were restricted to women
with abnormal glucose regulation. Thus, discrepant results
of current study and the study of Lawrence et al. may
suggestpathophysiologicaldiﬀerencesinpopulationssubject
to examinations [15].International Journal of Endocrinology 5
Table 2: Clinical and laboratory data for participants in studied groups: pGDM-P, pGDM-N and pNGT as a control group.
Variable (units) pGDM-P n = 29 pGDM-N n = 56 pNGT n = 40 P-values
Age (years) 31.50 (27.50–35.50) 30.00 (26.00–35.00) 27.00 (25.00–35.50) 0.1145
BMI (kg/m2) 25.12 (21.83–29.04)b 24.44 (21.26–27.22)a 22.00 (20.31–24.33) 0.0022
Waist circumference (cm) 80.00 (73.00–96.00)b 82.00 (73.00–90.00)a 74.50 (69.00−78.00) 0.0010
Fasting plasma glucose (mmol/L) 5.16 (4.77−5.88)b,c 4.77 (4.44−5.13) 4.72 (4.50−4.78) 0.0002
2-h (OGTT) plasma glucose (mmol/L) 8.27 (8.05−8.77)b,c 5.88 (5.44–6.66)a 4.84 (4.77–5.44) <0.0001
Insulin (pmol/L) 57.44 (42.36–95.84)cc 54.17 (41.67–69.45) 63.20 (54.87–71.53) 0.0353
sVCAM-1 (ng/mL) 960.30 (353.73–1638.03) 1127.63 (466.68–1582.58)a 672.05 (455.70–1113.46) 0.0553
sICAM-1 (ng/mL) 295.90 (238.80–363.38)b 299.28 (243.46–364.19)a 140.40 (121.34–179.90) <0.0001
sE-selectin (ng/mL) 35.80 (26.37–43.65)b 28.57 (20.35–42.54)a 20.90 (17.11–26.01) 0.0022
tPA:Ag (ng/mL) 6.01 (4.09–7.51)b 4.68 (3.25–7.24)a 3.50 (2.66–4.64) 0.0005
vWF:Ag (%) 107.79 (96.20–131.59) 104.30 (95.36–117.22) 104.87 (74.96–125.67) 0.6498
PAI-1:Ag (ng/mL) 57.67 (49.44–83.75) 57.09 (42.85–85.12) 71.36 (50.54–81.80) 0.2178
hsCRP (μg/mL) 1.30 (0.81–2.86)b 1.32 (0.66–2.76)a 0.41 (0.22–0.79) <0.0001
Total-cholesterol (mmol/L) 5.33 (4.84–5.92)b 5.02 (4.50–5.48)a 4.56 (4.27–5.09) 0.0022
HDL-cholesterol (mmol/L) 1.45 (1.29–1.73)b 1.55 (1.27–1.73)a 1.73 (1.56–1.82) 0.0048
LDL- cholesterol (mmol/L) 3.26 (2.97–4.06)b 3.03 (2.77–3.54)a 2.57 (2.30–3.05) <0.0001
Triglyceride (mmol/L) 1.21 (1.02–2.22)b,c 79.00 (63.00–116.00) 74.50 (58.50–91.00) 0.0004
Triglyceride/HDL cholesterol 1.83 (1.35–4.06)b,c 1.33 (0.95–2.30) 1.11 (0.89–1.50) 0.0003
HOMA-IR (mmol/L) 2.32 (1.27–3.49)ccc 1.64 (1.22–2.15) 1.89 (1.58–2.37) 0.0499
P-values for testing over the three groups (ANOVA): a: P<0.05 controls versus previous GDM with normal glucose regulation; b: P<0.05 controls versus
previous GDM with prediabetic state; c: P<0.05 previous GDM with normal glucose status versus previous GDM with prediabetic state, cc: P = 0.05, ccc:
P = 0.06.
Table 3: Plasma concentrations of endothelium markers according to low and high-glucose concentration within the prediabetic range.
Variable (units) Low glucose (n = 58) High glucose (n = 27) P-values
sVCAM (ng/mL) 849.78 (550.70–1285.55) 669.18 (419.60–13.90) 0.3610
sICAM (ng/mL) 222.44 (152.66–317.08) 247.79 (212.59–338.68) 0.1066
sE-selectin (ng/mL) 25.90 (19.03–40.17) 37.75 (27.93–46.15) 0.0314
0.0791∗
vWF:Ag (%) 101.72 (91.76–119.04) 107.10 (86.68–136.34) 0.3457
tPA:Ag (ng/mL) 4.05 (2.63–6.05) 4.92 (3.69–6.68) 0.0838
PAI-1:Ag (ng/mL) 61.85 (47.42–85.18) 55.47 (44.93–83.75) 0.7013
Values are median (IQR), and P values were from U Mann Whitney test. ∗Adjusted for body mass index.
4. Conclusion
Higher body fat indexes, glucose during OGTT, levels of
endothelial dysfunction biomarkers, low-grade inﬂamma-
tion (hscRP), and atherogenic dyslipidemia characterized
nondiabetic women with pGDM and normal glucose regu-
lation as well as women with pGDM and prediabetic state
assessed 2–24 months after delivery. Our ﬁndings indi-
cated that only parameters of atherogenic dyslipidemia and
sVCAM-1 level were associated with pGDM independently
of BMI, insulin resistance, and fasting glucose. sE-selectin
levels correlated with metabolic syndrome components but
were not independently associated with abnormal glucose
regulation. Thus, the atherogenic dyslipidemia may be the
key metabolic feature and a predictor of cardiovascular risk
in women with pGDM and thus needs early and regular
monitoring and special therapeutic interventions after an
index pregnancy.
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